What Is Glucocorticoid Remediable Aldosteronism?

Glucocorticoid remediable aldosteronism (GRA) is a rare inherited form of high blood pressure caused by a genetic mix-up between two closely related genes in the adrenal glands. The condition leads to overproduction of aldosterone, a hormone that drives the body to retain salt and water, and the defining feature is that this overproduction can be switched off by giving a low dose of a glucocorticoid drug like dexamethasone. First described in a father and son in 1966, GRA is now recognized as one of the few forms of hypertension with a single, well-understood genetic cause, yet it often goes undiagnosed for years because it can look like ordinary high blood pressure.

The Genetic Mix-Up That Causes GRA

Your adrenal glands sit on top of each kidney and are organized in layers, each producing different hormones. Two neighboring genes, CYP11B1 and CYP11B2, code for enzymes that work in different layers. CYP11B1 produces an enzyme involved in making cortisol in the zona fasciculata (the middle layer), while CYP11B2 produces aldosterone synthase in the zona glomerulosa (the outermost layer). These two genes are strikingly similar in their DNA sequence and sit right next to each other on chromosome 8.

During the formation of eggs or sperm, chromosomes line up and swap segments of DNA with their partner. Because CYP11B1 and CYP11B2 are so alike, they can misalign, and the swap happens in the wrong spot. The result is a hybrid gene that has the front end (the regulatory region) of CYP11B1 fused to the back end (the coding region) of CYP11B2. People who inherit this chimeric gene end up with three CYP11B genes on one chromosome instead of the usual two.¹ The practical consequence is that aldosterone synthase, which normally works only in the outer adrenal layer and responds to signals from the kidneys, is now active in the cortisol-producing middle layer and responds instead to ACTH, the pituitary hormone that regulates cortisol.²

GRA follows an autosomal dominant inheritance pattern, meaning you only need one copy of the chimeric gene from one parent to develop the condition. Each child of an affected parent has a 50 percent chance of inheriting it. The condition occurs equally in men and women and has been reported worldwide, though some early reports suggested it may be somewhat more common in people of Celtic ancestry.³

How GRA Drives High Blood Pressure

Under normal circumstances, aldosterone production is governed mainly by the renin-angiotensin system, a feedback loop that responds to blood volume and sodium levels. In GRA, the chimeric gene puts aldosterone production under the control of ACTH instead.⁴ ACTH follows a daily rhythm, peaking in the early morning hours, and it responds to stress. Because the pituitary gland keeps releasing ACTH as part of its normal job of stimulating cortisol, the adrenal glands in someone with GRA are constantly being told to make aldosterone as well.

Excess aldosterone tells the kidneys to hold on to sodium and water while dumping potassium. The retained fluid raises blood volume and, with it, blood pressure. Over time, this sustained pressure damages blood vessels and the heart. What makes GRA treatable is the flip side of this same mechanism: give the patient a small dose of a glucocorticoid like dexamethasone, and the pituitary senses the extra cortisol and dials back ACTH. With ACTH suppressed, the chimeric gene gets less stimulation, aldosterone drops, and blood pressure often normalizes.⁵

Signs and Symptoms

The hallmark of GRA is hypertension that begins early in life, often in childhood, and can be severe. A study of children diagnosed with GRA found that five out of eight already had serious hypertension by the time they were identified.⁶ The blood pressure can be stubborn, resisting the usual first-line medications doctors try. A family history of early-onset hypertension or stroke at a young age is one of the strongest clues.

One tricky aspect of GRA is that it does not always look like “classic” primary aldosteronism. Textbooks describe excess aldosterone as causing low potassium, but many GRA patients have perfectly normal potassium levels. In the same pediatric study, five of the eight children had normal potassium at diagnosis.⁶ This matters because clinicians who screen only patients with low potassium for aldosterone problems will miss a large share of GRA cases. Renin levels are typically suppressed, which is the expected finding when aldosterone is running high, but even that is not always dramatic enough to trigger suspicion.

Severity varies widely within the same family carrying the identical chimeric gene. Some relatives may have blood pressure that is only mildly elevated, while others develop life-threatening complications by their twenties or thirties. The reasons for this variability are not fully understood, though differences in salt intake, other genetic modifiers, and lifestyle factors likely play a role.

The Stroke and Aneurysm Threat

The most alarming complication of GRA is its strong link to hemorrhagic stroke and intracranial aneurysms at young ages. A registry study of 167 genetically confirmed GRA patients found 18 cerebrovascular events in 15 of them, while none occurred among 194 family members who did not carry the gene. About 70 percent of those events were hemorrhagic strokes, meaning bleeding in the brain rather than the clot-based strokes more common in the general population. The average age at the first event was roughly 32 years, and the case fatality rate was 61 percent.⁷

Overall, about half of all GRA families in the registry had at least one member with a cerebrovascular complication, and roughly one in five individual patients were affected. Those rates are strikingly high and comparable to the frequency of aneurysms seen in another well-known genetic condition, autosomal dominant polycystic kidney disease.⁷ The mechanism likely involves the combined damage of elevated aldosterone and high blood pressure on vessel walls. Research suggests that high tissue aldosterone levels, particularly when combined with salt intake, contribute to the weakening of arterial walls and the formation of aneurysms in both the brain and the aorta.⁵

These findings make the case for screening family members once GRA is identified in a household. A young person with undiagnosed GRA whose blood pressure goes uncontrolled may be at serious risk of a brain bleed before anyone realizes the cause. Some experts also recommend brain imaging to check for aneurysms in confirmed GRA patients, though screening protocols are not universally standardized.

How GRA Is Diagnosed

Because GRA is genetic, the definitive test is a genetic one. A blood sample is used to look for the chimeric CYP11B1/CYP11B2 gene using a targeted DNA amplification method. If the hybrid gene is present, it produces a distinctive DNA fragment that does not appear in unaffected family members.⁸ This test is highly specific and settles the diagnosis. Newer long-read sequencing methods have been developed that can not only detect the chimeric gene but also pinpoint exactly where the crossover occurred within the gene, which varies from family to family.⁹

Before genetic testing became readily available, doctors relied on the dexamethasone suppression test. The idea was simple: give the patient dexamethasone for a few days and see if aldosterone drops. If it does, the aldosterone must have been ACTH-dependent, pointing to GRA. The problem is that this test is not perfectly reliable. When researchers tested it on patients with aldosterone-producing adenomas (a common, non-genetic cause of excess aldosterone), a third of them also showed substantial aldosterone suppression after dexamethasone, which would lead to a false diagnosis of GRA.¹⁰ For that reason, genetic testing has become the gold standard, and the dexamethasone suppression test is mainly used as a preliminary screen in settings where genetic testing is not immediately available.

GRA patients also produce unusually high levels of two hybrid steroid hormones, 18-oxocortisol and 18-hydroxycortisol, which are byproducts of the chimeric enzyme acting on cortisol precursors. Elevated levels of these steroids in urine or blood can raise suspicion, though they are not exclusive to GRA and can also be elevated in another rare form of familial hyperaldosteronism.¹¹

Treatment Options

The treatment that gives GRA its name is glucocorticoid therapy. Low-dose dexamethasone or prednisone, taken once daily (often at bedtime to suppress the early-morning ACTH surge), can bring aldosterone levels down and normalize blood pressure. The key word is “low-dose.” The goal is to use just enough glucocorticoid to quiet ACTH without causing the side effects of cortisol excess, like weight gain, bone thinning, and blood sugar problems. In children especially, doctors are cautious because even small glucocorticoid doses over years can affect growth.

For patients who cannot tolerate glucocorticoids or who need additional blood pressure control, several alternatives exist. Mineralocorticoid receptor blockers like spironolactone and eplerenone counteract aldosterone’s effects on the kidney directly, regardless of how much is being produced. Amiloride and triamterene work by blocking the sodium channel in the kidney that aldosterone activates. Both approaches lower blood pressure and correct any potassium loss, but they do not reduce aldosterone levels themselves.¹² Many patients end up on a combination, using a small glucocorticoid dose alongside one of these agents, to keep blood pressure controlled without pushing either drug to a dose that causes side effects.

Unlike some forms of primary aldosteronism caused by a benign tumor in one adrenal gland, GRA cannot be cured with surgery. The chimeric gene is present in every cell of the body and affects both adrenal glands, so removing one would not solve the problem. Lifelong medication is the reality, along with regular monitoring of blood pressure, potassium, and overall adrenal function.

GRA During Pregnancy

Managing GRA in pregnancy presents a unique challenge. Spironolactone is generally avoided in pregnancy because it can cross the placenta and interfere with the development of a male fetus. Eplerenone appears to be a safer alternative among mineralocorticoid receptor blockers if one is needed, though the first approach is typically to manage blood pressure with standard pregnancy-safe antihypertensive drugs and potassium supplementation.¹³

Low-dose dexamethasone has been used successfully in at least one reported case involving a woman from a family with severe GRA, including members who had suffered fatal aortic dissection and early strokes. She was managed throughout her pregnancy on low-dose dexamethasone with good results.¹⁴ Still, the evidence base is thin, consisting of individual case reports rather than large trials, so decisions about medication in pregnant GRA patients are made case by case with close specialist oversight.

How GRA Fits Among Other Familial Aldosterone Disorders

GRA is classified as familial hyperaldosteronism type I (FH-I). There are other types. Familial hyperaldosteronism type II (FH-II) also runs in families with an autosomal dominant pattern and causes excess aldosterone, but the critical difference is that aldosterone in FH-II does not respond to dexamethasone. The genetic basis of FH-II involves different genes and does not involve the chimeric CYP11B1/CYP11B2 gene that defines GRA.¹⁵ Familial hyperaldosteronism type III, caused by mutations in a potassium channel gene, is even rarer and tends to produce extremely high aldosterone levels that may require surgical removal of the adrenal glands.

These distinctions matter clinically because the treatment paths diverge sharply. A patient misdiagnosed with FH-II when they actually have GRA would miss out on the straightforward glucocorticoid treatment that could control their condition. Conversely, treating someone with FH-II using dexamethasone would expose them to glucocorticoid side effects without any benefit. Genetic testing can resolve the question cleanly.

Why These Particular Genes Are So Prone to Errors

The CYP11B1 and CYP11B2 genes are what geneticists call “twin genes.” They arose from an ancient duplication event and still share roughly 95 percent of their DNA sequence. This high degree of similarity, combined with their physical proximity on chromosome 8, makes them especially vulnerable to the kind of misalignment during cell division that creates the chimeric gene behind GRA. The same general phenomenon affects another pair of adrenal genes, the CYP21 pair, where misalignment causes congenital adrenal hyperplasia, a far more common condition.¹⁶

This vulnerability is essentially a trade-off of genome architecture. Having two closely related genes side by side allows for specialized functions in different adrenal layers, but it also creates an ongoing risk of recombination errors in every generation. The chimeric gene that causes GRA is not inherited from some ancient ancestor who had the mutation; it arises fresh through new crossover events, which is why GRA can appear in families with no prior history, though most diagnosed cases are found through family screening after one member is identified. The crossover point within the gene varies between families, which is why newer sequencing methods that can pinpoint the exact breakpoint have become valuable for research and, increasingly, for clinical care.⁹

When to Suspect GRA

GRA is rare enough that most doctors will never see a case, but it is probably underdiagnosed. Current guidelines for evaluating primary aldosteronism generally recommend considering genetic testing for GRA in patients who develop aldosterone excess at a young age (particularly before age 20), who have a family history of primary aldosteronism, or who have a family history of stroke at a young age, especially hemorrhagic stroke. The condition was first recognized in 1966 when Sutherland and colleagues described a father and son with hypertension and low potassium whose aldosterone was entirely regulated by ACTH and correctable with glucocorticoids.¹⁷ It took three decades after that initial description for the genetic cause to be fully worked out, and awareness among general practitioners still lags behind the availability of testing.

If you or a family member have been diagnosed with high blood pressure that started unusually early, that resists standard treatment, or that comes alongside a family pattern of strokes or heart problems at young ages, it is worth asking your doctor whether genetic testing for GRA makes sense. The test is straightforward, and if it comes back positive, effective treatment exists. The real danger of GRA lies not in the condition being untreatable but in it going unrecognized while silent vascular damage accumulates.

1
PubMed. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2
2
PubMed Central. Genetic analyses of the chimeric CYP11B1/CYP11B2 gene in a Korean family with glucocorticoid-remediable aldosteronism
3
Endocrine Abstracts. Glucocorticoid remediable aldosteronism. A Northern Ireland experience
4
ScienceDirect. Glucocorticoid-Remediable Aldosteronism
5
PubMed Central. A Case of Glucocorticoid Remediable Aldosteronism and Thoracoabdominal Aneurysms
6
PubMed. Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood
7
PubMed. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism
8
PubMed. A chimeric CYP11B1/CYP11B2 gene in glucocorticoid-insuppressible familial hyperaldosteronism
9
PubMed Central. GRAde: a long-read sequencing approach to efficiently identifying the CYP11B1/CYP11B2 chimeric form in patients with glucocorticoid-remediable aldosteronism
10
PubMed. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism
11
PubMed Central. 18-Oxocortisol and 18-hydroxycortisol: is there clinical utility of these steroids?
12
Arquivos Brasileiros de Endocrinologia & Metabologia. Glucocorticoid-remediable aldosteronism – Section: TREATMENT
13
European Journal of Endocrinology. PROGRESS IN PRIMARY ALDOSTERONISM: Mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy
14
PubMed. Familial hyperaldosteronism type 1 and pregnancy: successful treatment with low dose dexamethasone
15
PubMed. New genetic insights in familial hyperaldosteronism
16
Acta Endocrinologica. Twin genes and endocrine disease: CYP21 and CYP11B genes
17
The Journal of Clinical Endocrinology & Metabolism. Glucocorticoid-Remediable Aldosteronism